Rashtriya Vayoshri Yojana: Assessment camp of senior citizens at Bhavnagar hospital
It is an initiative by Union Minister of State (Consumer Affairs, Food and Public Distribution) Nimuben Bambhaniya, who is also an MP from Bhavnagar-Botad constituency.
As per an official release, during the first two days of the camp, 2,655 beneficiaries have been identified for assistive devices worth over Rs 43 lakh.
The camp has been organised with the support of the Ujjain's production centre of Artificial Limb Manufacturing Corporation of India (ALIMCO), the release stated. Assistive devices like walking sticks, walkers, wheelchairs, hearing aids, artificial dentures, orthopaedic belts, commode chairs, etc. are provided free of cost to senior citizens aged above 60, it added.
Similar camps will be held at different taluka centres of the Lok Sabha constituency between July 4 and 15.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
&w=3840&q=100)
Business Standard
6 minutes ago
- Business Standard
Govt panel starts drafting rules for refurbished medical device imports
An inter-departmental high-level committee of the central government has begun discussions on new rules to regulate the entry of refurbished or second-hand medical devices into India. Valued at Rs 1,500 crore, industry executives estimate that the pre-owned medical equipment market accounts for around 10 per cent of the total medical equipment industry in the country. Sources told Business Standard that while only a couple of meetings have taken place so far, the committee is reviewing data related to the pre-owned or refurbished devices market. Officials confirmed that the panel includes representatives from the Ministry of Health and Family Welfare, Directorate General of Health Services (DGHS), the Central Drugs Standard Control Organisation (CDSCO), the Department of Pharmaceuticals, and industry stakeholders. This follows a communication by CDSCO to the Principal Commissioner of Customs in January 2025, acknowledging that there was no specific regulation for refurbished devices under the Medical Devices Rules (MDR), 2017. 'MDR 2017 has a provision for import of medical devices and the requirements are well set for this. The regulation does not differentiate between new and refurbished medical devices,' a health ministry official said. Currently, such imports are allowed through no-objection certificates from an expert committee of the Ministry of Environment, Forest and Climate Change (MoEFCC). The approvals are limited to 38 high-end and high-value (HEHV) medical equipment items listed by the DGHS. Imports are subject to conditions such as ensuring that equipment has not been phased out in the exporting country, contains no hazardous materials, and has a residual life of at least seven years. 'Major points to be discussed by the committee may include the service time of second-hand devices eligible for import or allowing only very expensive, high-end critical care equipment,' an official said. Confirming the development, MoEFCC sources said that while existing MDR provisions do not cover refurbished equipment, the health ministry is drafting regulatory mechanisms to support ease of doing business in the sector. 'MoHFW has shared a draft proposal with MoEFCC for comments,' the person added. Pre-owned medical devices largely include robotic-assisted surgery systems, linear accelerators, and CT scanners, which help meet demand in Tier-II, Tier-III, Tier-IV cities and underserved areas. While proponents argue that refurbished alternatives provide affordable solutions for smaller cities, several lobby groups and domestic manufacturers have urged the ministry to stop unregulated imports of high-risk second-hand medical equipment citing patient safety concerns. The Patient Safety and Access Initiative of India Foundation (PSAIIF), a Delhi-based not-for-profit organisation, has also filed a public interest litigation in the Delhi High Court, raising concerns over the reliability of these devices and risks to patient safety.
Business Standard
22 minutes ago
- Business Standard
Glenmark Pharma's US arm to launch Micafungin injection in the US market
Glenmark Pharmaceuticals announced that its U.S.-based subsidiary, Glenmark Pharmaceuticals Inc., USA, will launch Micafungin for Injection USP, 50 mg/vial and 100 mg/vial (Single-Dose Vial), in the U.S. market this September. The product is bioequivalent and therapeutically equivalent to the reference listed drug Mycamine for Injection, 50 mg/vial and 100 mg/vial, originally developed by Astellas Pharma US, Inc. The company will begin distribution in September 2025. According to IQVIA sales data for the 12-month period ending June 2025, the U.S. market for Mycamine for Injection generated annual sales of approximately $60.7 million. Micafungin is an echinocandin antifungal used primarily in the treatment of candidemia, esophageal candidiasis, and for prophylaxis of Candida infections in patients undergoing hematopoietic stem cell transplantation. Marc Kikuchi, president & business head, North America said, We are excited to announce the launch of Micafungin for Injection USP, 50 mg/vial and 100 mg/vial (Single-Dose Vial), growing our portfolio of products within the institutional channel, while also strengthening our commitment to bring quality and affordable alternatives to market for patients in need. Glenmarks Micafungin for Injection USP, 50 mg/vial and 100 mg/vial (Single-Dose Vial) is only approved for the indication listed in Glenmarks approved label. All brand names and trademarks are the property of their respective owners. Market includes brand and all available therapeutic equivalents. Note: IQVIA data obtained by Glenmark is only available for all approved RLD indications. Glenmarks product is only approved for the indications listed in Glenmarks approved label and is not marketed for all RLD indications. IQVIA National Sales Perspectives: Retail & Non-Retail, June 2025. Glenmark Pharmaceuticals is a research-led, global pharmaceutical company, having a presence across Branded, Generics, and OTC segments; with a focus on therapeutic areas of respiratory, dermatology and oncology. The company's consolidated net profit jumped 49.9% to Rs 215.48 crore on 7.4% rise in revenue from operations to Rs 1505.62 crore in Q1 FY26 over Q1 FY25. The scrip declined 1.38% to Rs 1,947.10 on the BSE.
Business Standard
2 hours ago
- Business Standard
Kopran Ltd Spurts 4.13%
Kopran Ltd has lost 8.09% over last one month compared to 0.96% fall in BSE Healthcare index and 0.54% drop in the SENSEX Kopran Ltd gained 4.13% today to trade at Rs 163.7. The BSE Healthcare index is up 0.34% to quote at 44693.47. The index is down 0.96 % over last one month. Among the other constituents of the index, Aarti Pharmalabs Ltd increased 2.6% and Rainbow Childrens Medicare Ltd added 1.58% on the day. The BSE Healthcare index went up 7.92 % over last one year compared to the 1.11% surge in benchmark SENSEX. Kopran Ltd has lost 8.09% over last one month compared to 0.96% fall in BSE Healthcare index and 0.54% drop in the SENSEX. On the BSE, 25 shares were traded in the counter so far compared with average daily volumes of 20242 shares in the past one month. The stock hit a record high of Rs 369.2 on 09 Sep 2024. The stock hit a 52-week low of Rs 156.5 on 08 Aug 2025.
